Cargando…

Sex Differences in Oxycodone/Naloxone vs. Tapentadol in Chronic Non-Cancer Pain: An Observational Real-World Study

Despite the large body of research on sex differences in pain, there is a lack of translation to real-world pain management. Our aim was to analyse the sex differences in the analgesic response to oxycodone/naloxone (OXN) and tapentadol (TAP), in comparison with other opioids (OPO) commonly prescrib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barrachina, Jordi, Margarit, Cesar, Muriel, Javier, López-Gil, Vicente, López-Gil, Santiago, Ballester, Pura, Mira-Lorente, Laura, Agulló, Laura, Peiró, Ana M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598624/ https://www.ncbi.nlm.nih.gov/pubmed/36289731 http://dx.doi.org/10.3390/biomedicines10102468

Ejemplares similares

Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study
por: Barrachina, Jordi, et al.
Publicado: (2022)

Methodological Issues on a Clinical Trial to Test Tapentadol Prolonged release vs. Oxycodone/Naloxone Prolonged release
por: Bacallao, Jorge, et al.
Publicado: (2016)

Tapentadol vs oxycodone/naloxone in the management of pain after total hip arthroplasty in the fast track setting: an observational study
por: D’Amato, Tiziana, et al.
Publicado: (2019)

Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone
por: Haeseler, Gertrud, et al.
Publicado: (2017)

Impact of CYP2D6 genotype on opioid use disorder deprescription: an observational prospective study in chronic pain with sex-differences
por: Muriel, Javier, et al.
Publicado: (2023)

Tapentadol and Oxycodone/Naloxone Prescribing Patterns in Primary Health Care in Catalonia, Spain: A Cross-Sectional Study
por: Viñas-Bastart, Montserrat, et al.
Publicado: (2021)

Tapentadol shows lower intrinsic efficacy at µ receptor than morphine and oxycodone
por: Manandhar, Preeti, et al.
Publicado: (2022)

Sex-Differences in Pain and Opioid Use Disorder Management: A Cross-Sectional Real-World Study
por: Escorial, Mónica, et al.
Publicado: (2022)

The place of oxycodone/naloxone in chronic pain management
por: Leppert, Wojciech
Publicado: (2013)

CYP2D6 Genotype and Pharmacovigilance Impact on Autism Spectrum Disorder: A Naturalistic Study with Extreme Phenotype Analysis
por: Ballester, Pura, et al.
Publicado: (2023)

Comparison of Real-world Outcomes Between Patients Treated with Tapentadol ER or Oxycodone CR
por: Durkin, Mike, et al.
Publicado: (2015)

Opioid-Induced Bowel Dysfunction in Patients Undergoing Spine Surgery: Comparison of Oxycodone and Oxycodone-Naloxone Treatment
por: Kokki, Merja, et al.
Publicado: (2016)

Treatment of Opioid Withdrawal Syndrome Triggered by Oxycodone/Naloxone with Dexmedetomidine
por: Go, Se-Il, et al.
Publicado: (2023)

Web-Based Discussion and Illicit Street Sales of Tapentadol and Oxycodone in Australia: Epidemiological Surveillance Study
por: Black, Joshua, et al.
Publicado: (2021)

Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis
por: Lazzari, Marzia, et al.
Publicado: (2015)

Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350
por: Poulsen, Jakob L, et al.
Publicado: (2018)

Influence of tapentadol and oxycodone on the spinal cord and brain using electrophysiology: a randomized, placebo‐controlled trial
por: Nedergaard, Rasmus Bach, et al.
Publicado: (2022)

Pain therapy with oxycodone/naloxone prolonged-release combination: case report
por: Błaszczyk, Feliks, et al.
Publicado: (2013)

Intractable restless legs syndrome: role of prolonged-release oxycodone–naloxone
por: de Biase, Stefano, et al.
Publicado: (2016)

Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice
por: Ueberall, Michael A, et al.
Publicado: (2016)

Comparison of the Risks of Shopping Behavior and Opioid Abuse Between Tapentadol and Oxycodone and Association of Shopping Behavior and Opioid Abuse
por: Cepeda, M. Soledad, et al.
Publicado: (2014)

Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users
por: Colucci, Salvatore V., et al.
Publicado: (2014)

Combined Administration of Oxycodone/Naloxone in Chronic Osteo-Articular Diseases Pain Therapy
por: Rosa, Palomba, et al.
Publicado: (2014)

Developments in managing severe chronic pain: role of oxycodone–naloxone extended release
por: Fanelli, Guido, et al.
Publicado: (2015)

A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR
por: Dupoiron, D., et al.
Publicado: (2017)

Outcomes Associated with Treatment of Chronic Pain with Tapentadol Compared with Morphine and Oxycodone: A UK Primary Care Observational Study
por: Morgan, Christopher Ll., et al.
Publicado: (2019)

Sex Differences in Opioid Response Linked to OPRM1 and COMT genes DNA Methylation/Genotypes Changes in Patients with Chronic Pain
por: Agulló, Laura, et al.
Publicado: (2023)

Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence
por: DePriest, Anne Z., et al.
Publicado: (2014)

Assessment of Neurotoxic Effects of Oxycodone and Naloxone in SH-SY5Y Cell Line
por: Lima, Luíza Siqueira, et al.
Publicado: (2023)

Endothelial nitric oxide synthase gene polymorphisms and erectile dysfunction in chronic pain
por: Segura, Ana, et al.
Publicado: (2019)

Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations
por: Ueberall, Michael A, et al.
Publicado: (2016)

Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial
por: Lee, Kyung-Hee, et al.
Publicado: (2017)

Pharmacogenetic Guided Opioid Therapy Improves Chronic Pain Outcomes and Comorbid Mental Health: A Randomized, Double-Blind, Controlled Study
por: Agulló, Laura, et al.
Publicado: (2023)

Oxycodone/naloxone as a therapeutic option in a patient with chronic pain and opioid-induced bowel dysfunction
por: Kraj, Leszek, et al.
Publicado: (2014)

Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain
por: Sandner-Kiesling, A, et al.
Publicado: (2010)

Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients
por: Guerriero, Fabio, et al.
Publicado: (2014)

Quality of Life and Healthcare Resource in Patients Receiving Opioids for Chronic Pain: A Review of the Place of Oxycodone/Naloxone
por: Morlion, Bart, et al.
Publicado: (2014)

Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: an observational analysis
por: De Santis, Stefano, et al.
Publicado: (2016)

Analgesic Efficacy and Safety of Prolonged-Release Oxycodone/Naloxone in Korean Patients with Chronic Pain from Spinal Disorders
por: Hwang, Chang Ju, et al.
Publicado: (2018)

Transition from Oxycodone to Buprenorphine/Naloxone in a Hospitalized Patient with Sickle Cell Disease: A Case Report
por: Leyde, Sarah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4258rkvb7h5jr44c3o7sbnbceq